It consists of a humanised IgG4 mAb conjugated to a calicheamicin payload that targets the CD33 surface antigen, which is present in 85–90% of individuals with acute myeloid leukaemia [88]. This evidence concerns the gene CD33 and acute myeloid leukemia.